Manavi M
SURMOUNT-5: Tirzepatide shows superior weight loss over semaglutide owenhaskins May 12, 2025 2 min read Seventy-two week outcomes from the SURMOUNT-5 clinical trial have shown that tirzepatide (Zepbound) met the primary endpoint and all five key secondary endpoints, demonstrating superiority, compared to semaglutide (Wegovy) across the trial
Just to give context to GLP-1, when a woman has lymph nodes removed for breast cancer treatment, and radiated often, you're physically removing that pathway that's carrying the fluid out of the arm
We believe that understanding the nuance between ingredients like glutathione and L-glutathione allows you to spend your wellness budget more effectively and achieve better results
Sasaki H, Sato H, Kuriyama-Matsumura K, Sato K, Maebara K, Wang H, et al
Samulak JJ, Sawicka AK, Hartmane D, Grinberga S, Pugovics O, Lysiak-Szydlowska W, et al